Premium
Precision Medicine in Inflammatory Bowel Diseases
Author(s) -
Fischer Sarah,
Neurath Markus F.
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.793
Subject(s) - inflammatory bowel diseases , medicine , intensive care medicine , inflammatory bowel disease , clinical trial , crohn's disease , ulcerative colitis , disease
Inflammatory bowel diseases (IBDs) are a lifelong condition of chronic, recurrent inflammation in the gut. The introduction of immunomodulators and biologic agents markedly improved the treatment of IBDs. Therefore, the use of biologics became an essential element in the rational therapy of IBDs. Various substances are currently evaluated in clinical trials, addressing different target structures and offering further approaches in the field of IBD. Regarding the growing number of treatment options, the need for prediction of therapy response became a necessity and is the subject of the present research.